{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:13:35Z","timestamp":1792592015699,"version":"4.5.0"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Hypertriglyceridemia (HTG), a form of dyslipidemia characterized by elevated plasma of triglycerides (TG), is associated with an increased risk for acute pancreatitis. Moreover, HTG has recently been shown to be linked to the development of atherosclerotic cardiovascular disease (ASCVD); therefore, there is a great interest in better understanding the pathophysiology of HTG and improving its clinical management. In this review, we briefly describe TG metabolism, recent guidelines for the clinical management of HTG and provide an overview of the current and potential new therapies for HTG.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Screening patients for HTG is valuable for not only identifying patients with extreme TG elevations, who are at risk for pancreatitis, but also for managing ASCVD risk in patients with more moderate forms of HTG. Therefore, the most recent USA guidelines for cardiovascular diseases recommend using TG as a risk enhancer test, leading to a more aggressive treatment of patients with intermediate risk. Currently, there are several available approaches for reducing plasma TG, which include lifestyle changes, fibrates and omega-3 fatty acid treatment. The addition of eicosapentaenoic acid (EPA) on top of statins has recently been shown to significantly reduce ASCVD events. Nevertheless, there is an unmet need for more effective treatment options. Several new therapies based on newly identified targets in TG metabolism, such as apolipoprotein C-III and angiopoietin-like 3 protein, are currently under development.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The clinical management of HTG is important in the prevention and treatment of acute pancreatitis and also impacts on how ASCVD risk is managed. More work needs to be done to establish the mechanism for the ability of how EPA lowers ASCVD and how to best integrate it with other lipid-lowering therapies. The efficacy and safety of the novel therapies for HTG should be established soon in the ongoing late-stage clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000710","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T10:01:29Z","timestamp":1602064889000},"page":"331-339","source":"Crossref","is-referenced-by-count":40,"title":["Hypertriglyceridemia: new approaches in management and treatment"],"prefix":"10.1097","volume":"31","author":[{"given":"Anna","family":"Wolska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated nonfasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"J\u00f8rgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ajcn\/nqy304","article-title":"Fasting hepatic de novo lipogenesis is not reliably assessed using circulating fatty acid markers","volume":"109","author":"Rosqvist","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MOL.0000000000000297","article-title":"Role of lipoprotein lipase in lipid metabolism","volume":"27","author":"Olivecrona","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1074\/jbc.M808477200","article-title":"The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms","volume":"284","author":"Shan","year":"2009","journal-title":"J Biol Chem"},{"key":"R9-20230917","first-page":"e1082","article-title":"2018\u200aAHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"R10-20230917","article-title":"Hypertriglyceridemia Management According to the 2018 AHA\/ACC Guideline","author":"Jacobsen","year":"2019","journal-title":"Expert Analysis"},{"key":"R11-20230917","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/MOL.0000000000000680","article-title":"Apolipoprotein C-II: the re-emergence of a forgotten factor","volume":"31","author":"Wolska","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2019","journal-title":"Eur Heart J"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jacl.2020.01.014","article-title":"Chylomicronemia syndrome: familial or not?","volume":"14","author":"Warden","year":"2020","journal-title":"J Clin Lipidol"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jacl.2016.03.048","article-title":"Acute pancreatitis is highly prevalent and complications can be fatal in patients with familial chylomicronemia: results from a survey of lipidologist","volume":"10","author":"Gaudet","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jacl.2018.04.009","article-title":"The burden of familial chylomicronemia syndrome: results from the global IN-FOCUS study","volume":"12","author":"Davidson","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R16-20230917","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12944-020-01302-x","article-title":"The burden of familial chylomicronemia syndrome in Canadian patients","volume":"19","author":"Gaudet","year":"2020","journal-title":"Lipids Health Dis"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.106.637793","article-title":"Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies","volume":"115","author":"Sarwar","year":"2007","journal-title":"Circulation"},{"key":"R18-20230917","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2018.04.061","article-title":"Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management","volume":"72","author":"Ganda","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jacl.2018.04.010","article-title":"Familial chylomicronemia syndrome: bringing to life dietary recommendations throughout the life span","volume":"12","author":"Williams","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019\u200aESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ajcn\/84.1.5","article-title":"n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review","volume":"84","author":"Wang","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/nu9080865","article-title":"Omega-3 fatty acids and cardiovascular disease: summary of the 2016 Agency of Healthcare Research and Quality Evidence Review","volume":"9","author":"Balk","year":"2017","journal-title":"Nutrients"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3945\/ajcn.110.003871","article-title":"Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridemia","volume":"93","author":"Skulas-Ray","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12944-015-0049-7","article-title":"A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals","volume":"14","author":"Leslie","year":"2015","journal-title":"Lipids Health Dis"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopha.2014.10.008","article-title":"Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals: a randomized cross-over trial","volume":"68","author":"Miyoshi","year":"2014","journal-title":"Biomed Pharmacother"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1210\/jc.2016-2217","article-title":"omega-3 fatty acid ethyl esters diminish postprandial lipemia in familial hypercholesterolemia","volume":"101","author":"Chan","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3390\/nu12030749","article-title":"Comparison of omega-3 eicosapentaenoic acid versus docosahexaenoic acid-rich fish oil supplementation on plasma lipids and lipoproteins in normolipidemic adults","volume":"12","author":"Yang","year":"2020","journal-title":"Nutrients"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/ajcn\/66.3.649","article-title":"Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids","volume":"66","author":"Grimsgaard","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"R31-20230917","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ajcn\/76.2.326","article-title":"The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans","volume":"76","author":"Nestel","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jacl.2011.10.018","article-title":"Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review","volume":"6","author":"Jacobson","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-nutr-071812-161139","article-title":"Fatty acid-regulated transcription factors in the liver","volume":"33","author":"Jump","year":"2013","journal-title":"Annu Rev Nutr"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1194\/jlr.M200282-JLR200","article-title":"Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance","volume":"44","author":"Park","year":"2003","journal-title":"J Lipid Res"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1073\/pnas.0707460104","article-title":"Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control","volume":"105","author":"Pan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jjcc.2017.07.007","article-title":"A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins","volume":"70","author":"Watanabe","year":"2017","journal-title":"J Cardiol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Group","year":"2018","journal-title":"N Engl J Med"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plefa.2018.01.001","article-title":"Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Chang","year":"2018","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1210\/jc.2017-02745","article-title":"High-dose DHA has more profound effects on LDL-related features than high-dose EPA: the ComparED study","volume":"103","author":"Allaire","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R46-20230917","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"R47-20230917","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jacl.2017.04.043","article-title":"Natural history (up to 15 years) of platelet count in 84 patients with familial hyperchylomicronemia due to lipoprotein lipase deficiency","volume":"11","author":"Gaudet","year":"2017","journal-title":"J Clin lipidology"},{"key":"R48-20230917","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/ATVBAHA.118.312028","article-title":"Moving targets: recent advances in lipid-lowering therapies","volume":"39","author":"Larsen","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R49-20230917","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"R50-20230917","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"R51-20230917","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc(3)-conjugated 2\u2019-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"R54-20230917","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1007\/s40265-017-0818-x","article-title":"Pemafibrate: first global approval","volume":"77","author":"Blair","year":"2017","journal-title":"Drugs"},{"key":"R55-20230917","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jacl.2018.06.010","article-title":"Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia","volume":"12","author":"Yamashita","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R56-20230917","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5551\/jat.48918","article-title":"Clinical applications of a novel selective PPAR\u03b1 modulator, pemafibrate, in dyslipidemia and metabolic diseases","volume":"26","author":"Yamashita","year":"2019","journal-title":"J Atheroscler Thromb"},{"key":"R57-20230917","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/dom.13686","article-title":"Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study","volume":"21","author":"Araki","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"R58-20230917","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","article-title":"Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion","volume":"56","author":"Wang","year":"2015","journal-title":"J Lipid Res"},{"key":"R59-20230917","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/nm.4390","article-title":"A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels","volume":"23","author":"Khetarpal","year":"2017","journal-title":"Nat Med"},{"key":"R60-20230917","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1124\/jpet.114.220418","article-title":"A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice","volume":"352","author":"Amar","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"R61-20230917","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1124\/jpet.115.229740","article-title":"Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptide","volume":"356","author":"Sakurai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R62-20230917","doi-asserted-by":"crossref","first-page":"7078241","DOI":"10.1155\/2019\/7078241","article-title":"Apolipoprotein C-II mimetic peptide promotes the plasma clearance of triglyceride-rich lipid emulsion and the incorporation of fatty acids into peripheral tissues of mice","volume":"2019","author":"Komatsu","year":"2019","journal-title":"J Nutr Metab"},{"key":"R63-20230917","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bbrc.2019.08.130","article-title":"Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach","volume":"519","author":"Reimund","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"R64-20230917","doi-asserted-by":"crossref","first-page":"eaaw7905","DOI":"10.1126\/scitranslmed.aaw7905","article-title":"A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides","volume":"12","author":"Wolska","year":"2020","journal-title":"Sci Transl Med"},{"key":"R65-20230917","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"key":"R66-20230917","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1194\/jlr.P800061-JLR200","article-title":"Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia","volume":"50","author":"Tremblay","year":"2009","journal-title":"J Lipid Res"},{"key":"R67-20230917","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"R68-20230917","doi-asserted-by":"crossref","first-page":"20b","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T07:08:29Z","timestamp":1694934509000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOL.0000000000000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000710","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]}}}